Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Post by talisman47on Jan 30, 2021 12:25am
229 Views
Post# 32427293

Algernon facebook post late today

Algernon facebook post late today

put on their facebook site late Friday.....

#AlgernonCase: An independent research review named Ifenprodil as a drug with high affinity at the sigma-1 receptor, a key therapeutic target involving SARS-CoV-2 replication.
This discovery adds to our confidence in Ifenprodil as a potential therapeutic: https://bit.ly/36dXFKN
 

 

 
May be an image of text that says 'ALGERNON PHARMACEUTICALS #AlgernonCase Ifenprodil (NP-120) Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor Proposed the repurposing of traditional central nervous system drugs that have high affinity at the sigma-1 receptor Focused on the sigma-1 receptor and its important role in SARS-COV-2 replication Named Ifenprodil as a potential treatment SARS-COV-2 infected patients CSE:AGN AGN FRANKFURT:AGW OTCQB: AGNPF'
 
 
 
 
 
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities